Cisplatin
Platinol · Platinum agent
Proximal tubular ATN + magnesium wasting; the archetype.
ATNLYTEPRE
SevereOpen →
Antitumor antibiotic
Bleomycin
Blenoxane · Bleo
A glycopeptide antibiotic prized for marrow-sparing cancer kill, whose renal excretion makes the failing kidney a setup for runaway exposure and lethal lung toxicity, not a direct nephron target.
Mild1970s antibiotic · approved 1973
Testicular and other germ-cell tumors (BEP/EP)Hodgkin lymphoma (ABVD)Squamous-cell carcinoma of head/neck, cervix, skinMalignant pleural effusion (sclerotherapy)
Signature kidney injury
Acute Tubular Necrosis
Bleomycin is not a classic direct nephrotoxin; the actionable renal issue is exposure-driven. Roughly two-thirds of a dose is cleared renally, and terminal half-life rises exponentially once creatinine clearance falls below ~25-35 mL/min, magnifying systemic (especially pulmonary) toxicity. Direct kidney injury is not well quantified and is largely confounded by co-administered cisplatin.
Source: Crooke et al., Cancer Treat Rep 1977
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityMild
ReversibilityVariable
Evidence0 refs
Nephron map
Glomerulus
Vasculature / Endothelium
Proximal TubuleBulk reabsorption + drug uptake (OCT2, OATs)
Distal Tubule / Collecting DuctFine-tuning of Na, K, Mg, acid & water
Acute Tubular Necrosis
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Mechanism of kidney injury
There is no well-characterized direct tubular toxin mechanism. The dominant renal concern is pharmacokinetic: bleomycin is predominantly renally eliminated, so declining GFR causes drug accumulation and exponentially prolonged half-life, increasing the risk of dose-dependent toxicities (notably pulmonary fibrosis). Any AKI seen in BEP regimens is generally attributable to concurrent cisplatin (tubular injury) or prerenal insults, with bleomycin contributing chiefly by exposure amplification.
Clinical presentation
Renal presentation is usually that of the regimen rather than the drug: declining GFR, electrolyte wasting and prerenal physiology from cisplatin and vomiting. Bleomycin's own exposure-driven toxicity manifests as pulmonary (cough, dyspnea, infiltrates) rather than renal signs. Rising serum creatinine should prompt dose/exposure review because it predicts heightened systemic toxicity.
Onset
Pharmacokinetic accumulation is immediate in renal impairment; clinical (pulmonary) toxicity is cumulative over weeks to months.
Reversibility
Variable
Anticancer mechanism
Bleomycin is a Streptomyces-derived glycopeptide antitumor antibiotic that chelates iron and oxygen to generate reactive oxygen species, producing single- and double-strand DNA breaks; it is cell-cycle phase-specific (G2/M). Because it causes minimal myelosuppression, it anchors curative combinations such as BEP (bleomycin, etoposide, cisplatin) for germ-cell tumors and ABVD for Hodgkin lymphoma, and is also used in squamous-cell carcinomas and as a sclerosant for malignant effusions.
Management
Manage the underlying cause of declining renal function (hold/adjust cisplatin, restore volume). Reduce bleomycin exposure in renal impairment and monitor closely for pulmonary toxicity, which is the clinically dangerous consequence of accumulation. There is no specific antidote; supportive care and discontinuation if toxicity emerges.
Risk factors
- Pre-existing renal impairment (CrCl <35 mL/min)
- Concurrent cisplatin (reduces bleomycin clearance and is itself nephrotoxic)
- High cumulative bleomycin dose
- Older age
- Volume depletion from chemotherapy-induced vomiting
Prevention
- Accurate GFR assessment before and during therapy (note eGFR equations are unreliable during platinum chemotherapy)
- Dose reduction in renal impairment
- Maintain hydration and treat prerenal insults
- Limit cumulative dose; monitor for pulmonary toxicity which exposure rise potentiates
Note · The renal story for bleomycin is one of clearance and exposure, not a signature nephron lesion. In germ-cell survivors, long-term nephrotoxicity is driven mainly by cisplatin, with bleomycin contributing to pulmonary morbidity.
Clinical depth
Renal dose adjustment
Reduce dose in renal impairment; common guidance reduces by ~25% for CrCl 40-50 mL/min and progressively more (up to ~50-60%) for CrCl 10-40 mL/min, reflecting the exponential rise in half-life below ~25-35 mL/min. Verify against local protocol.
Dialyzability & ESKD dosing
Low-molecular-weight and water-soluble; case-level data suggest some removal by dialysis, but it is not relied upon clinically. Dosing in dialysis patients should be conservative and individualized.
Differential diagnosis
Distinguish exposure-driven systemic toxicity from cisplatin-induced ATN and electrolyte wasting (the usual cause of AKI in BEP), prerenal azotemia from vomiting, and tumor-related obstruction. Bleomycin itself rarely produces an isolated nephron lesion.
Monitoring
- Serum creatinine / measured or estimated GFR before each cycle
- Pulmonary function tests and symptoms (the key exposure-driven toxicity)
- Cumulative bleomycin dose tracking
- Electrolytes (in context of platinum co-therapy)
Key trials & series
- Crooke et al. 1977 — renal-function-dependent bleomycin pharmacokinetics (half-life rises exponentially below CrCl 25-35 mL/min)
- Broughton et al. 1977 — renal clearance correlates with creatinine clearance; markedly elevated steady-state levels and 33-h half-life in renal impairment
- Lauritsen et al. 2014 — unreliability of eGFR during BEP chemotherapy
Clinical pearls
- About two-thirds of bleomycin is excreted in urine, so a falling GFR sharply prolongs its half-life and amplifies pulmonary toxicity.
- A rising creatinine on BEP is a red flag for dose adjustment, not primarily because of bleomycin nephrotoxicity but because accumulation worsens lung injury.
- eGFR equations are unreliable during platinum-based chemotherapy because creatinine and true GFR fall together — consider measured GFR.
- Cisplatin co-administration further reduces bleomycin clearance, compounding exposure.
Where it strikes
Nephron segments
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Glomerulus
Filtration barrier (podocytes + endothelium)
Injury signatures
Acute Tubular NecrosisElectrolyte WastingPrerenal / Hemodynamic AKI
Beyond the kidney
Class-level context for the major non-renal toxicities of antitumor antibiotics.
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Mitomycin / bleomycin pulmonary toxicity
Hematologic
Cytopenias, thrombosis, TMA
- Cumulative myelosuppression
Evidence
4 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkEffects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus.Crooke ST et al. · Cancer Treat Rep 1977 · PMID 74282Terminal half-life of bleomycin rises exponentially once creatinine clearance falls below ~25-35 mL/min — the core exposure-driven rationale for renal dose adjustment.PMIDClinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay.Broughton A et al. · Cancer 1977 · PMID 73408Renal bleomycin clearance correlates with creatinine clearance; a renally impaired patient reached markedly elevated steady-state levels and a 33-h half-life.PMIDReliability of estimated glomerular filtration rate in patients treated with platinum containing therapy.Lauritsen J et al. · Int J Cancer 2014 · PMID 24585507Shows eGFR equations are unreliable during BEP chemotherapy because creatinine and measured GFR fall together — critical to dosing renally cleared agents like bleomycin.PMIDPhysical long-term side-effects in young adult cancer survivors: germ cell tumors model.Kourie HR et al. · Curr Opin Oncol 2017 · PMID 28463858Reviews long-term nephrotoxicity and pulmonary toxicity in germ-cell tumor survivors treated with bleomycin-containing (BEP) regimens.